These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24277680)

  • 1. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.
    Kupčová V; Arold G; Roepstorff C; Højbjerre M; Klim S; Haahr H
    Clin Drug Investig; 2014 Feb; 34(2):127-33. PubMed ID: 24277680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin degludec: pharmacokinetics in patients with renal impairment.
    Kiss I; Arold G; Roepstorff C; Bøttcher SG; Klim S; Haahr H
    Clin Pharmacokinet; 2014 Feb; 53(2):175-83. PubMed ID: 24163264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
    Korsatko S; Deller S; Mader JK; Glettler K; Koehler G; Treiber G; Urschitz M; Wolf M; Hastrup H; Søndergaard F; Haahr H; Pieber TR
    Drugs Aging; 2014 Jan; 31(1):47-53. PubMed ID: 24263619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
    Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
    Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
    Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
    Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes.
    Biester T; Danne T; Bläsig S; Remus K; Aschemeier B; Kordonouri O; Bardtrum L; Haahr H
    Pediatr Diabetes; 2016 Dec; 17(8):642-649. PubMed ID: 26782928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes.
    Biester T; Blaesig S; Remus K; Aschemeier B; Kordonouri O; Granhall C; Søndergaard F; Kristensen NR; Haahr H; Danne T
    Pediatr Diabetes; 2014 Feb; 15(1):27-33. PubMed ID: 24467565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
    Heise T; Korsatko S; Nosek L; Coester HV; Deller S; Roepstorff C; Segel S; Kapur R; Haahr H; Hompesch M
    J Diabetes; 2016 Jan; 8(1):132-8. PubMed ID: 25581159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec.
    Haahr H; Cieslarová B; Hingst JR; Jiang S; Kristensen NR; Kupčová V; Nørgreen L; Wagner FH; Ignatenko S
    Clin Pharmacokinet; 2024 Jun; 63(6):819-830. PubMed ID: 38722461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of BMI on Pharmacokinetic and Pharmacodynamic Parameters of Insulin Degludec: Results from an Euglycemic Glucose Clamp Study.
    Li T; Liu H; Li S; Yu H; Li J; Tan H; Yu Y
    Clin Pharmacokinet; 2023 Mar; 62(3):449-456. PubMed ID: 36738401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
    Korsatko S; Deller S; Koehler G; Mader JK; Neubauer K; Adrian CL; Thomsen H; Haahr H; Pieber TR
    Clin Drug Investig; 2013 Jul; 33(7):515-21. PubMed ID: 23749405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the pharmacological properties of insulin degludec and their clinical relevance.
    Haahr H; Heise T
    Clin Pharmacokinet; 2014 Sep; 53(9):787-800. PubMed ID: 25179915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
    Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
    Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.